Table Filtering
Other Information
Release Statistics Download
GlyCosmos Glycolipids

Glycolipid entries from the LIPID MAPS Structure Database (LMSD).

Source Last Updated
LIPID MAPS Proteome Database (LMSD) June 16, 2024
Displaying entries 1276 - 1300 of 3913 in total
Main Class Sub Class LM ID Name LipidBank ID KEGG ID PubChem CID ChEBI ID Exact Mass ▲ Formula
Neutral glycosphingolipids Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AF05
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
  • type I A antigen(d18:1/24:0)
44260656 1688.012427 C82H149N3O32
Neutral glycosphingolipids Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AK05
  • Fucalpha1-4GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44260696 1688.012427 C82H149N3O32
Neutral glycosphingolipids Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AR05
  • GlcNAcbeta1-3Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44260752 1688.012427 C82H149N3O32
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AF05
  • GalNAcbeta1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
  • type II A antigen(d18:1/24:0)
44261016 1688.012427 C82H149N3O32
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CG05
  • ClcNAc-Lex-5(d18:1/24:0)
  • GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44261440 1688.012427 C82H149N3O32
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CU05
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
  • type II A antigen(d18:1/24:0)
44261544 1688.012427 C82H149N3O32
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BI05
  • Fucalpha1-3GlcNAcbeta1-3Galalpha1-3(GalNAcbeta1-4)Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44261696 1688.012427 C82H149N3O32
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BB03
  • GalNAcalpha1-3GalNAcbeta1-3(GalNAcbeta1-4)Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44260382 1688.971291 C80H144N4O33
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AL03
  • GalNAcalpha1-3GalNAcbeta1-3Galalpha1-3(GlcNAcbeta1-6)Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44261902 1688.971291 C80H144N4O33
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AQ08
  • GalNAcbeta1-3Galalpha1-3Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44260299 1688.996443 C82H148N2O33
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BF08
  • Galalpha1-3Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44260419 1688.996443 C82H148N2O33
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BA08
  • Galalpha1-3Galbeta1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44261635 1688.996443 C82H148N2O33
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AQ06
  • GalNAcbeta1-3Galalpha1-3Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44260297 1691.012093 C82H150N2O33
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BF06
  • Galalpha1-3Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44260417 1691.012093 C82H150N2O33
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BA06
  • Galalpha1-3Galbeta1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44261633 1691.012093 C82H150N2O33
Acidic glycosphingolipids Gangliosides LMSP0601BD02
  • Fuc-GM1(d18:1/18:0)
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-4(NeuAcalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44262197 1691.934572 C79H141N3O35
Acidic glycosphingolipids Gangliosides LMSP0601CH02
  • NeuAcalpha2-3Galbeta1-3(Fucalpha1-4)GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
  • Sialyl-Lea(d18:1/18:0)
44262429 1691.934572 C79H141N3O35
Acidic glycosphingolipids Gangliosides LMSP0601DL02
  • NeuAcalpha2-3Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
  • sialyl-Lea(d18:1/18:0)
44262637 1691.934572 C79H141N3O35
Acidic glycosphingolipids Gangliosides LMSP0601DS02
  • Galbeta1-3(NeuAcalpha2-6)(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44262693 1691.934572 C79H141N3O35
Acidic glycosphingolipids Gangliosides LMSP0601EE02
  • NeuAcalpha2-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
  • sialyl-Lex(d18:1/18:0)
44262781 1691.934572 C79H141N3O35
Acidic glycosphingolipids Gangliosides LMSP0601AF01
  • NeuGcalpha2-3Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44262004 1695.893102 C77H137N3O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AK01
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0)
  • type IV B antigen(d18:1/16:0)
44260244 1696.913503 C78H140N2O37
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BC01
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44261644 1696.913503 C78H140N2O37
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AW02
  • Galalpha1-3Galalpha1-3Galalpha1-3Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44260341 1699.913169 C78H141NO38
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AF07
  • Galbeta1-3(GlcNAcbeta1-6)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44260210 1701.991692 C82H147N3O33

About Release Notes Help Feedback

Click here to visit the beta site.


International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.0.0

Last updated: August 19, 2024